Response to Comment on Delphi Analysis of Relevant Comparators in a Cost-Effectiveness Model of Prostate Cancer Screening

Pharmacoeconomics. 2021 Aug;39(8):969-970. doi: 10.1007/s40273-021-01062-1. Epub 2021 Jul 17.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cost-Benefit Analysis
  • Early Detection of Cancer*
  • Humans
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms* / diagnosis
  • Quality-Adjusted Life Years

Substances

  • Prostate-Specific Antigen